磁共振动态增强扫描在前列腺癌诊断中的应用价值

研究磁共振动态增强扫描在前列腺癌诊断中的应用价值。方法 选取2020年1月~2021年2月到我院接受治疗的40例疑似前列腺癌患者作为研究对象,按随机分组法,对照组中20例采用电子计算机断层扫描(CT),观察组中20例采用磁共振动态增强扫描(MRI)。观察统计两组患者前列腺癌诊断效能、灵敏性、特异性、准确性。结果 观察组前列腺癌的诊断效能、灵敏性、特异性以及准确性均显著优于对照组(P<0.05)。结论 将磁共振动态增强扫描运用到前列腺癌的诊断中,其灵敏性、特异性、准确性都很高,能对患者前列腺癌进行准确的诊断,值得临床应用推广。

乳腺钼靶、核磁DWI与DCE在乳腺占位性病变诊断中的价值

目的:探究了乳腺钼靶X线、核磁共振弥散扩权成像(DWI)联合动态增强扫描(DCE)技术用于乳腺占位性病变诊断的应用价值。方法:选取90例乳腺肿物患者(2021年12月~2022年12月)作为研究对象。行乳腺钼靶X线检查、核磁共振DWI联合DCE技术诊断、联合诊断,比较三种检查方式的诊断效能。结果:乳腺钼靶X线诊断恶性病变,敏感度、特异度、准确性分别为75.61%、81.63%、78.89%。核磁共振DWI联合DCE技术诊断恶性病变,敏感度、特异度、准确性分别为85.37%、85.71%、85.56%。乳腺钼靶X线、核磁共振DWI联合DCE诊断结果恶性病变,敏感度、特异度、准确性分别为90.24%、95.92%、93.33%。乳腺钼靶X线、核磁共振DWI联合DCE诊断结果恶性病变的准确率,显著高于乳腺钼靶X线,高于核磁共振DWI联合DCE技术,差异均有统计学意义。结论:乳腺钼靶X线检查、核磁共振DWI联合DCE技术诊断、三者联合诊断,对乳腺占位性病变取得了较准确的诊断结果,诊断效能高于X线检查、核磁共振DWI联合DCE技术诊断,临床应用价值较高。

Detection of small hepatocellular carcinoma:Comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning

AIM: To compare the gadolinium-enhanced multiphase dynamic magnetic resonance imaging (MRI) and multiphase multirow-detector helical CT (MDCT) scanning for detection of small hepatocellular carcinoma (HCC). METHODS: MDCT scanning and baseline MRI with SE T1-WI and T2-WI sequence combined with FMPSPGR sequence were performed in 37 patients with 43 small HCCs. Receiver operating characteristic (ROC) curves were plotted to analyze the results for modality. RESULTS: The areas below ROC curve (Az) were calculated. There was no statistical difference in dynamic enhancement MDCT and MRI. The detection rate of small HCC was 97.5%-97.6% on multiphase MDCT scanning and 90.7%-94.7% on MRI, respectively. The sensitivity of detection for small HCC on MDCT scanning was higher than that on dynamic enhancement MRI. The sensitivity of detection for minute HCC (tumor diameter ≤ 1 cm) was 90.0%-95.0% on MDCT scanning and 70.0%-85.0% on MRI, respectively. CONCLUSION: MDCT scanning should be performed for early detection and effective treatment of small HCC in patients with chronic hepatitis and cirrhosis during follow-up.